Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

MT newswireMT newswire2026/09/03 13:13
09:13 AM EDT, 09/03/2026 (MT Newswires) -- AbbVie (ABBV) said Thursday that it has completed its acquisition of Apogee Therapeutics (APGE), valuing the clinical-stage biotechnology company at about $10.9 billion, or $135.11 per share. The acquisition is expected to negatively impact adjusted diluted earnings per share by $0.14 in 2026 and by approximately $0.46 in 2027, with accretion beginning in 2032, AbbVie said. Apogee Therapeutics' stock ceased trading on the Nasdaq stock exchange prior to the market open on Sept. 3, according to a statement. AbbVie said it continues to expect Q3 adjusted diluted EPS in the range of $3.84 to $3.88, and full-year adjusted diluted EPS between $13.87 to $14.07. Analysts polled by FactSet expect $3.86 and $14.03, respectively.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!